APO Research
Talk to an analyst

APO RESEARCH · REPORT

Latent Tuberculosis Infection (LTBI) Testing

The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc.

Across the world, the major players cover Qiagen, Oxford Immunotec, Sanofi, etc.

Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination. Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI.

Selected research

Market Analysis & Forecast

Global Latent Tuberculosis Infection (LTBI) Testing Market Analysis and Forecast 2026-2032

28 December 2025194 pages

Choose your research edition.

Industry ResearchLatent Tuberculosis Infection (LTBI) Testing Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Latent Tuberculosis Infection (LTBI) Testing Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Latent Tuberculosis Infection (LTBI) Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Latent Tuberculosis Infection (LTBI) Testing Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Latent Tuberculosis Infection (LTBI) Testing Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc.

Across the world, the major players cover Qiagen, Oxford Immunotec, Sanofi, etc.

Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination. Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI.

Read the full market overview

The detection industry of latent tuberculosis infection (LTBI) can be subdivided into several parts: tuberculin skin test (TST), interferon release test (IGRA), etc.

Globally, there are mainly Qiagen, Oxford Immunotec, Sanofi, etc.

Diagnosing and treating latent tuberculosis infection (LTBI) is an important strategy recognized by the World Health Organization to accelerate the decline of global tuberculosis and achieve the elimination of tuberculosis. Latent tuberculosis infection (LTBI) refers to the state of continuous immune response to the stimulation of Mycobacterium tuberculosis antigen in the absence of clinical evidence of active tuberculosis (TB). The diagnosis and treatment of long-term tuberculosis is very important for tuberculosis, especially for high-risk groups. Tuberculin skin tests (TST) and interferon release tests (IGRAs) were used to diagnose LTBI.

Report Includes

This report presents an overview of global market for Latent Tuberculosis Infection (LTBI) Testing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Latent Tuberculosis Infection (LTBI) Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for Latent Tuberculosis Infection (LTBI) Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Latent Tuberculosis Infection (LTBI) Testing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Latent Tuberculosis Infection (LTBI) Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Latent Tuberculosis Infection (LTBI) Testing revenue, projected growth trends, production technology, application and end-user industry.

Latent Tuberculosis Infection (LTBI) Testing Segment by Company

Qiagen

Sanofi

Oxford Immunotec

Thermo Fisher Scientific

Par Sterile

Bio-Rad Laboratories

Latent Tuberculosis Infection (LTBI) Testing Segment by Type

Tuberculin Skin Test (TST)

Interferon Gamma Released Assay (IGRA)

Latent Tuberculosis Infection (LTBI) Testing Segment by Application

Hospitals and Clinics

Diagnostic Laboratories

Others

Latent Tuberculosis Infection (LTBI) Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Latent Tuberculosis Infection (LTBI) Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Latent Tuberculosis Infection (LTBI) Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Latent Tuberculosis Infection (LTBI) Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Latent Tuberculosis Infection (LTBI) Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Latent Tuberculosis Infection (LTBI) Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Latent Tuberculosis Infection (LTBI) Testing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tuberculin Skin Test (TST) Major Player Table 3. Interferon Gamma Released Assay (IGRA) Major Player Table 4. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospitals and Clinics Major Player Table 6. Diagnostic Laboratories Major Player Table 7. Others Major Player Table 8. Latent Tuberculosis Infection (LTBI) Testing Industry Trends Table 9. Latent Tuberculosis Infection (LTBI) Testing Industry Drivers Table 10. Latent Tuberculosis Infection (LTBI) Testing Industry Opportunities and Challenges Table 11. Latent Tuberculosis Infection (LTBI) Testing Industry Restraints Table 12. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Latent Tuberculosis Infection (LTBI) Testing Market Share by Region (2021-2026) Table 15. Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Latent Tuberculosis Infection (LTBI) Testing Market Share by Region (2027-2032) Table 17. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Players (2021-2026) Table 19. Global Latent Tuberculosis Infection (LTBI) Testing Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Latent Tuberculosis Infection (LTBI) Testing Key Players Headquarters & Area Served Table 21. Global Latent Tuberculosis Infection (LTBI) Testing Players, Product Type & Application Table 22. Global Latent Tuberculosis Infection (LTBI) Testing Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Latent Tuberculosis Infection (LTBI) Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2021-2026) Table 29. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2027-2032) Table 30. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2021-2026) Table 34. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2027-2032) Table 35. Qiagen Company Information Table 36. Qiagen Business Overview Table 37. Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Qiagen Latent Tuberculosis Infection (LTBI) Testing Product Portfolio Table 39. Qiagen Recent Development Table 40. Sanofi Company Information Table 41. Sanofi Business Overview Table 42. Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Sanofi Latent Tuberculosis Infection (LTBI) Testing Product Portfolio Table 44. Sanofi Recent Development Table 45. Oxford Immunotec Company Information Table 46. Oxford Immunotec Business Overview Table 47. Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Product Portfolio Table 49. Oxford Immunotec Recent Development Table 50. Thermo Fisher Scientific Company Information Table 51. Thermo Fisher Scientific Business Overview Table 52. Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Product Portfolio Table 54. Thermo Fisher Scientific Recent Development Table 55. Par Sterile Company Information Table 56. Par Sterile Business Overview Table 57. Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Par Sterile Latent Tuberculosis Infection (LTBI) Testing Product Portfolio Table 59. Par Sterile Recent Development Table 60. Bio-Rad Laboratories Company Information Table 61. Bio-Rad Laboratories Business Overview Table 62. Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Product Portfolio Table 64. Bio-Rad Laboratories Recent Development Table 65. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2026) & (US$ Million) Table 66. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2027-2032) & (US$ Million) Table 67. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2026) & (US$ Million) Table 68. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2027-2032) & (US$ Million) Table 69. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 70. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021-2026) & (US$ Million) Table 71. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (US$ Million) & (2027-2032) Table 72. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2026) & (US$ Million) Table 73. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2027-2032) & (US$ Million) Table 74. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2026) & (US$ Million) Table 75. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2027-2032) & (US$ Million) Table 76. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 77. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021-2026) & (US$ Million) Table 78. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (US$ Million) & (2027-2032) Table 79. China Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2026) & (US$ Million) Table 80. China Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2027-2032) & (US$ Million) Table 81. China Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2026) & (US$ Million) Table 82. China Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2026) & (US$ Million) Table 84. Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2027-2032) & (US$ Million) Table 85. Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2026) & (US$ Million) Table 86. Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2027-2032) & (US$ Million) Table 87. Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Region (US$ Million) & (2021-2026) Table 89. Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Region (US$ Million) & (2027-2032) Table 90. SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2026) & (US$ Million) Table 91. SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2027-2032) & (US$ Million) Table 92. SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2026) & (US$ Million) Table 93. SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2027-2032) & (US$ Million) Table 94. SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021-2026) & (US$ Million) Table 96. SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (US$ Million) & (2027-2032) Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Latent Tuberculosis Infection (LTBI) Testing Image Figure 2. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tuberculin Skin Test (TST) Image Figure 5. Interferon Gamma Released Assay (IGRA) Image Figure 6. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospitals and Clinics Image Figure 9. Diagnostic Laboratories Image Figure 10. Others Image Figure 11. Global Latent Tuberculosis Infection (LTBI) Testing Market Size (US$ Million) & (2021-2032) Figure 12. Global Latent Tuberculosis Infection (LTBI) Testing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Latent Tuberculosis Infection (LTBI) Testing Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Latent Tuberculosis Infection (LTBI) Testing Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2021-2032) Figure 19. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2021-2032) Figure 22. North America Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Type (2021-2032) Figure 24. North America Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Application (2021-2032) Figure 25. North America Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Country (2021-2032) Figure 26. United States Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Type (2021-2032) Figure 31. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Application (2021-2032) Figure 32. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Country (2021-2032) Figure 33. Germany Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Type (2021-2032) Figure 43. China Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Application (2021-2032) Figure 44. Asia Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Type (2021-2032) Figure 46. Asia Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Application (2021-2032) Figure 47. Asia Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Region (2021-2032) Figure 48. Japan Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Type (2021-2032) Figure 56. SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Application (2021-2032) Figure 57. SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Country (2021-2032) Figure 58. Brazil Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Latent Tuberculosis Infection (LTBI) Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Tuberculin Skin Test (TST)
  • Interferon Gamma Released Assay (IGRA)
Applications
  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Others
Companies covered
  • Qiagen
  • Sanofi
  • Oxford Immunotec
  • Thermo Fisher Scientific
  • Par Sterile
  • Bio-Rad Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Latent Tuberculosis Infection (LTBI) Testing Market by Type
  3. 1.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tuberculin Skin Test (TST)
  5. 1.2.3 Interferon Gamma Released Assay (IGRA)
  6. 1.3 Latent Tuberculosis Infection (LTBI) Testing Market by Application
  7. 1.3.1 Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospitals and Clinics
  9. 1.3.3 Diagnostic Laboratories
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Latent Tuberculosis Infection (LTBI) Testing Market Dynamics
  1. 2.1 Latent Tuberculosis Infection (LTBI) Testing Industry Trends
  2. 2.2 Latent Tuberculosis Infection (LTBI) Testing Industry Drivers
  3. 2.3 Latent Tuberculosis Infection (LTBI) Testing Industry Opportunities and Challenges
  4. 2.4 Latent Tuberculosis Infection (LTBI) Testing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Latent Tuberculosis Infection (LTBI) Testing Market Perspective (2021-2032)
  2. 3.2 Global Latent Tuberculosis Infection (LTBI) Testing Growth Trends by Region
  3. 3.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Region (2021-2026)
  5. 3.2.3 Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Players
  2. 4.1.1 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Players (2021-2026)
  3. 4.1.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Latent Tuberculosis Infection (LTBI) Testing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Latent Tuberculosis Infection (LTBI) Testing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Latent Tuberculosis Infection (LTBI) Testing Key Players Headquarters & Area Served
  7. 4.4 Global Latent Tuberculosis Infection (LTBI) Testing Players, Product Type & Application
  8. 4.5 Global Latent Tuberculosis Infection (LTBI) Testing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Latent Tuberculosis Infection (LTBI) Testing Market CR5 and HHI
  11. 4.6.3 2025 Latent Tuberculosis Infection (LTBI) Testing Tier 1, Tier 2, and Tier 3
5 Latent Tuberculosis Infection (LTBI) Testing Market Size by Type
  1. 5.1 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2032)
  3. 5.3 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2021-2032)
6 Latent Tuberculosis Infection (LTBI) Testing Market Size by Application
  1. 6.1 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2032)
  3. 6.3 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Qiagen
  2. 7.1.1 Qiagen Company Information
  3. 7.1.2 Qiagen Business Overview
  4. 7.1.3 Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Qiagen Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
  6. 7.1.5 Qiagen Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Oxford Immunotec
  14. 7.3.1 Oxford Immunotec Company Information
  15. 7.3.2 Oxford Immunotec Business Overview
  16. 7.3.3 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
  18. 7.3.5 Oxford Immunotec Recent Developments
  19. 7.4 Thermo Fisher Scientific
  20. 7.4.1 Thermo Fisher Scientific Company Information
  21. 7.4.2 Thermo Fisher Scientific Business Overview
  22. 7.4.3 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
  24. 7.4.5 Thermo Fisher Scientific Recent Developments
  25. 7.5 Par Sterile
  26. 7.5.1 Par Sterile Company Information
  27. 7.5.2 Par Sterile Business Overview
  28. 7.5.3 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
  30. 7.5.5 Par Sterile Recent Developments
  31. 7.6 Bio-Rad Laboratories
  32. 7.6.1 Bio-Rad Laboratories Company Information
  33. 7.6.2 Bio-Rad Laboratories Business Overview
  34. 7.6.3 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
  36. 7.6.5 Bio-Rad Laboratories Recent Developments
8 North America
  1. 8.1 North America Latent Tuberculosis Infection (LTBI) Testing Revenue (2021-2032)
  2. 8.2 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2032)
  3. 8.2.1 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2026)
  4. 8.2.2 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2027-2032)
  5. 8.3 North America Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Type (2021-2032)
  6. 8.4 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2032)
  7. 8.4.1 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2026)
  8. 8.4.2 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2027-2032)
  9. 8.5 North America Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Application (2021-2032)
  10. 8.6 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country
  11. 8.6.1 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021-2026)
  13. 8.6.3 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue (2021-2032)
  2. 9.2 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2032)
  3. 9.2.1 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2026)
  4. 9.2.2 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2027-2032)
  5. 9.3 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Type (2021-2032)
  6. 9.4 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2032)
  7. 9.4.1 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2026)
  8. 9.4.2 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2027-2032)
  9. 9.5 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Application (2021-2032)
  10. 9.6 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Country
  11. 9.6.1 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021-2026)
  13. 9.6.3 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Latent Tuberculosis Infection (LTBI) Testing Revenue (2021-2032)
  2. 10.2 China Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2032)
  3. 10.2.1 China Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2026)
  4. 10.2.2 China Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2027-2032)
  5. 10.3 China Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Type (2021-2032)
  6. 10.4 China Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2032)
  7. 10.4.1 China Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2026)
  8. 10.4.2 China Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2027-2032)
  9. 10.5 China Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue (2021-2032)
  2. 11.2 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2032)
  3. 11.2.1 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2026)
  4. 11.2.2 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2027-2032)
  5. 11.3 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Type (2021-2032)
  6. 11.4 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2032)
  7. 11.4.1 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2026)
  8. 11.4.2 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2027-2032)
  9. 11.5 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Application (2021-2032)
  10. 11.6 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Country
  11. 11.6.1 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021-2026)
  13. 11.6.3 Asia Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue (2021-2032)
  2. 12.2 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2027-2032)
  5. 12.3 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2027-2032)
  9. 12.5 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Country
  11. 12.6.1 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst